

List of Study Group 2017-2018

2018

1. Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia: The JALSG-STIM213 Study. *Int J Hematol.* 2018; 107: 185-93.
2. Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. . *Int J Hematol.* 2018; 107: 656–65.
3. Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida S, Nakaya A, et al. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. *Int J Hematol.* 2018; 107: 541-50.
4. Nogami K, Takedani H, Shima M, Yoshioka A, Matsushita T, Takamatsu J, et al, Perioperative safety and hemostatic efficacy of Advate® in patients with hemophilia A in a postmarketing surveillance in Japan *Int J Hematol.* 2018; 108: 22–9.
5. Takahashi H, Kajiwara R, Kato M, Hasegawa D, Tomizawa D, Noguchi Y, et al. Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16. *Int J Hematol.* 2018; 108: 98–108.
6. Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, et al. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. *Int J Hematol.* 2018; 108: 192–8.

7. Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, et al. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. *Int J Hematol.* 2018; 108: 176–83.
8. Okamoto S, Teshima T, Kosugi-Kanaya M, Kahata K, Kawashima N, Kato J, et al. Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. *Int J Hematol.* 2018; 108: 298–305.
9. Itamura H, Ide M, Sato A, Sueoka-Aragane N, Sueoka E, Nishida A. Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. *Int J Hematol.* 2018; 108:416-22.
10. Taga T, Imamura T, Nakashima K, Maeda N, Watanabe A, Miyajima Y, et al. Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan. *Int J Hematol.* 2018; 108: 438–42.
11. Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, et al. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. *Int J Hematol.* 2018;108:499-509.

2017

1. Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, et al. Pediatric thromboembolism: a national survey in Japan. *Int J Hematol.* 2017; 105: 52-8.
2. Miyamoto T, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, et al. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood

transplantation. *Int J Hematol.* 2017; 105: 92-9.

3. Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, et al. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. *Int J Hematol.* 2017; 105:309-17.
4. Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, et al. Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. *Int J Hematol.* 2017; 105: 369-76.
5. Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, et al. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. *Int J Hematol.* 2017; 105:485-96.
6. Takahashi N, Nakaseko C, Kobayashi K, Miyamura K, Ono C, Koide Y, et al. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. *Int J Hematol.* 2017; 106:398-410.
7. Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, et al.. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. *Int J Hematol.* 2017; 106:375-84.
8. Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki K, et al.. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. *Int J Hematol.* 2017; 106: 655-65.

9. Miyagi-Maeshima A, Taniguchi H, Suzuki T, Yuda S, Toyoda K, Yamauchi N., et al. Distribution of malignant lymphomas in the anterior mediastinum: A single-institution study of 76 cases in Japan, 1997-2016. *Int J Hematol.* 2017; 106: 675-80.
10. Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, et al. Retrospective analysis of prognostic factors for Waldenström macroglobulinemia: a multicenter cooperative study in Japan. *Int J Hematol.* 2017; 106: 681–90.